Bluebird Bio down 35%, halted again for volatility

Bluebird Bio shares, which had been halted earlier ahead of the company announcing that the U.S. Food and Drug Administration has approved Lyfgenia, also known as lovo-cel, for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events, have resumed trading and subsequently halted several times for volatility. Shares were down $1.66, or 35%, to $3.15 at the last halt after the company announced a $3.1M wholesale acquisition cost of Lyfgenia and noted that the safety information for Lyfgenia included a boxed warning for hematologic malignancy.